Quarterly Result10 Aug 2026, 03:31 pm
Windlas Biotech Approves Unaudited Q1 FY27 Standalone Results
AI Summary
Windlas Biotech Ltd announced the approval of its Unaudited Standalone Financial Results for the quarter ended June 30, 2026. The Board of Directors met on August 10, 2026, to review and approve these results. The company also submitted the Limited Review Report from its auditors. A significant note indicates that the company is no longer required to prepare consolidated financial statements due to the dissolution of its US subsidiary, Windlas Inc., effective March 31, 2026.
Key Highlights
- Board approved Unaudited Standalone Financial Results for Q1 FY27.
- Results for the quarter ended June 30, 2026, were declared.
- Limited Review Report from auditors was submitted.
- Company no longer prepares consolidated statements.
- Dissolution of US subsidiary Windlas Inc. is complete.
Price Impact
More from WINDLAS*